摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methyl-N-(1-methylpiperidin-4-yl)-3-[(9-oxo-2,8,16,17,19,20-hexazatetracyclo[12.5.2.13,7.017,21]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-18-yl)amino]benzamide | 1012864-39-9

中文名称
——
中文别名
——
英文名称
N-methyl-N-(1-methylpiperidin-4-yl)-3-[(9-oxo-2,8,16,17,19,20-hexazatetracyclo[12.5.2.13,7.017,21]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-18-yl)amino]benzamide
英文别名
——
N-methyl-N-(1-methylpiperidin-4-yl)-3-[(9-oxo-2,8,16,17,19,20-hexazatetracyclo[12.5.2.13,7.017,21]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-18-yl)amino]benzamide化学式
CAS
1012864-39-9
化学式
C30H35N9O2
mdl
——
分子量
553.667
InChiKey
NBXKWJSFEKLBAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    41
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    119
  • 氢给体数:
    3
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    1-甲基-4-(甲氨基)哌啶 、 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 N-甲基吡咯烷酮 为溶剂, 生成 N-methyl-N-(1-methylpiperidin-4-yl)-3-[(9-oxo-2,8,16,17,19,20-hexazatetracyclo[12.5.2.13,7.017,21]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-18-yl)amino]benzamide
    参考文献:
    名称:
    Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities
    摘要:
    A series of macrocyclic derivatives has been designed and synthesized based on the X-ray co-crystal structures of pyrazolo[1,5-a] [1,3,5]triazines with corn CK2 (cCK2) protein. Bioassays demonstrated that these macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds are potent CK2 inhibitors with K-i around 1.0 nM and strongly inhibit cancer cell growth with IC50 as low as similar to 100 nM. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.11.074
点击查看最新优质反应信息

文献信息

  • Protein Kinase Inhibitors
    申请人:Chu Shaosong
    公开号:US20080070893A1
    公开(公告)日:2008-03-20
    Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds
    嘌呤和三嗪基化学化合物,例如作为蛋白激酶抑制剂用于治疗癌症、神经系统疾病、自身免疫性疾病和其他疾病,以及使用这些化合物的方法。
  • PROTEIN KINASE INHIBITORS
    申请人:Chu Shaosong
    公开号:US20090247501A1
    公开(公告)日:2009-10-01
    Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds
    嘌呤和三嗪基化学化合物,例如作为蛋白激酶抑制剂用于治疗癌症、神经系统疾病、自身免疫疾病和其他疾病,以及使用这些化合物的方法。
  • US7517882B2
    申请人:——
    公开号:US7517882B2
    公开(公告)日:2009-04-14
  • Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities
    作者:Zhe Nie、Carin Perretta、Philip Erickson、Stephen Margosiak、Jia Lu、April Averill、Robert Almassy、Shaosong Chu
    DOI:10.1016/j.bmcl.2007.11.074
    日期:2008.1
    A series of macrocyclic derivatives has been designed and synthesized based on the X-ray co-crystal structures of pyrazolo[1,5-a] [1,3,5]triazines with corn CK2 (cCK2) protein. Bioassays demonstrated that these macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds are potent CK2 inhibitors with K-i around 1.0 nM and strongly inhibit cancer cell growth with IC50 as low as similar to 100 nM. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多